Overview

* Zevra Q3 2025 revenue of $26.1 mln missed analyst expectations

* Net loss for Q3 2025 reduced significantly compared to Q3 2024

* Revenue growth driven by MIPLYFFA performance in Niemann-Pick disease type C

Outlook

* Company did not provide specific guidance for future quarters or years in press release

Result Drivers

* MIPLYFFA PERFORMANCE - MIPLYFFA contributed $22.4 mln to Q3 revenue, driving overall revenue growth

* OLPRUVA STRATEGY - Co scaling back OLPRUVA sales efforts due to limited market access, maintaining availability

* PIPELINE PROGRESS - EMA reviewing arimoclomol for NPC; Celiprolol Phase 3 trial enrollment ongoing

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $26.06 $26.63

Revenue mln mln (8

Analysts

)

Q3 Net -$544,00

Income 0

Q3 $4.14

Income mln

from

Operatio

ns

Q3 $20.37

Operatin mln

g

Expenses

Q3 -$977,00

Pretax 0

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Zevra Therapeutics Inc ( ZVRA ) is $25.00, about 60.8% above its November 4 closing price of $9.79

* The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 13 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)